Hopital Des Enfants — Clinical Trial Site

43 Registered trials

24 Currently recruiting

Organisation

Hopital Des Enfants

Location

Toulouse Cedex 9, France

Identifier

ORG-100026949

Address

330 Avenue De Grande Bretagne, 31059, France

Departments

-
#2102:Equipe de gastroentérologie, hépatologie, nutrition et maladies héréditaires du métabolisme
#2307: Pneumologie Pédiatrique et Allergologie
1904: Neurologie pédiatrique
2304: Pédiatrie
Cardiologie pédiatrique
CHU Toulouse - Hôpital des Enfants
CHU Toulouse, Endocrinology Unit, Obesity, Bone Diseases, genetics and Medical Gynecology
endocrinologie, gynécologie et génétique médicale
Endocrinology, Gynecology & Medical Genetics
Gastro-entérologie, hépatologie, nutrition et maladies héréditaires du métabolisme
Gastroenterology, Hepatology, Nutrition and Diseases Hereditary Metabolism
Hémato-Immmuno-Onco-Pediatry
Hopital des enfants Hematologie, oncologie
N/A
NA
Neurologie, Infectiologie Pédiatrique
Onco-pediatry
ONCOLOGIE
Oncology for pediatrics
Paediatric Oncology
PEDIATRIC ENDOCRINOLOGY
Pediatric Endocrinology Department
Pediatric Nephrology
Pediatric oncology
Pediatrics
Pédiatrie - Endocrinologie, génétique et gynécologie médicale
Pediatry
Pôle de Pédiatrie (Equipe Ressource Régionale de Soins Palliatifs Pédiatriques Midi-Pyrénées)
Recherche clinique Pédiatrique
Service d'Hémato-oncologie
Service de Gastroenterologie, Hepatologie, Nutrition et Maladies Hereditaires du Metabolisme
service de Neuropédiatrie
Service de Pédiatrie - Néphrologie, médecine interne et hypertension
Unité de Gastroentérologie, Hépatologie, Nutrition et Diabétologie pédiatriques
Unité de Neurologie
Urgences pédiatriques

Clinical trials at this site (43)

Search interface

A double-dummy, double-blind, randomized, active controlled, two-way cross-over study with 12-week treatment duration per period, to evaluat… Pending

2022-502365-26-00 Asthma 5
SPARE : Stopping Pneumonia Antibiotherapy Regimen Early Pending

2024-512236-30-00 Community-acquired alveolar pneumonia in children 5
BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending

2024-516115-24-00 High risk relapsed neuroblastoma (relapsed or progresse 9
A Phase 3 Open-Label Study to Investigate bexicaserin (LP352) in Children and Adults with Developmental and Epileptic Encephalopathy Recruiting

2024-514974-39-00 Developmental and Epileptic Encephalopathies (DEEs) 5 2025-10-10
A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Moderate to Severe Active Systemic Lupus Erythematosus 5 2024-08-28
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome Recruiting

2023-505140-19-00 Childhood Idiopathic Nephrotic Syndrome 5 2023-07-31
A Ph2 Superiority Study with InO Monotherapy vs ALLR3 for Induction Treatment of Childhood HR ALL Recruiting

2023-509810-13-00 Acute Lymphoblastic Leukemia (ALL) 4 2023-05-13
A phase 2/3, multicenter, randomized, double-blind study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of oral oza… Recruiting

2023-509248-86-00 Moderately to Severely Active Ulcerative Colitis 10 2022-03-11
Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in … Recruiting

2024-516807-17-00 Relapsing/Refractory ALK+ Anaplastic Large cell Lymphom 4 2019-01-02
Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia Recruiting

2023-504694-20-00 pediatric CD22-positive relapsed/refractory Acute Lymph 9 2017-01-13
Long-Term Extension Study of Vosoritide to Treat Children with Hypochondroplasia Recruiting

2024-517238-16-00 Hypochondroplasia 5 2026-01-28
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature Recruiting

2024-520137-74-00 Idiopathic Short Stature (ISS) 4 2025-10-10
Long Term Study of Livmarli Recruiting

2024-516804-40-00 Progressive Familial Intrahepatic Cholestasis 6 2025-09-25
A Phase 3, placebo-controlled study to investigate LP352 in children and adults with Developmental and Epileptic Encephalopathies Recruiting

2024-516412-17-00 Developmental and Epileptic Encephalopathies (DEE) 5 2025-08-26
A Phase III study to evaluate the efficacy of INM004 (Shiga antitoxin) in pediatric patients with Shiga toxin-producing Escherichia coli-ass… Recruiting

2024-512412-22-00 Hemolytic Uremic Syndrome 5 2025-06-24
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) Recruiting

2024-514937-39-00 Dravet Syndrome 5 2025-05-20
A Basket Study of Vosoritide in Children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome with I… Recruiting

2024-515861-33-00 Turner Syndrome, Short Stature Homeobox-Containing Gene 4 2025-03-25
A Phase 3 Efficacy and Safety Study of Pitolisant in Patients with Prader-Willi Syndrome Recruiting

2023-508307-21-00 Prader-Willi syndrome 5 2025-03-19
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high… Recruiting

2022-501344-14-00 Paediatric Patients with Severe Eosinophilic Asthma Ast 5 2023-06-05
Long-term safety and tolerability of inclisiran in participants with heterozygous familial hypercholesterolaemia or homozygous familial hype… Recruiting

2023-507278-41-00 Familial hypercholsterolemia 5 2023-02-10
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Ch… Recruiting

2024-512382-13-00 Migraine (with or without aura) 5 2022-10-04
A study to evaluate long-term Infigratinib in children with Achondroplasia Recruiting

2024-513857-55-00 Achondroplasia 4 2022-02-08
International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the effica… Recruiting

2022-501454-11-00 standard risk ALK-positive anaplastic large cell lympho 5 2020-02-05